Infection of Novel Coronavirus in Patients with DiabetesMellitus
- Authors: Sukanya Tripathy1, Sanjay Singh2, Durgesh Dubey3, Monisha Banerjee4, Dinesh Raj Modi5, Anand Prakash6
-
View Affiliations Hide Affiliations1 Department of Biotechnology, Babasaheb Bhimrao Ambedkar University, Lucknow, India | Molecular and Human Genetics Laboratory, Department of Zoology, University of Lucknow,Lucknow, India 2 Department of Biotechnology, Babasaheb Bhimrao Ambedkar University, Lucknow, India 3 Department of Biotechnology, Babasaheb Bhimrao Ambedkar University, Lucknow, India 4 Molecular and Human Genetics Laboratory, Department of Zoology, University of Lucknow, Lucknow, India 5 Department of Biotechnology, Babasaheb Bhimrao Ambedkar University, Lucknow, India 6 Department of Biotechnology, Mahatma Gandhi Central University Bihar, Motihari, India
- Source: Pharmacological and Molecular Perspectives on Diabetes , pp 81-93
- Publication Date: April 2022
- Language: English
Infection of Novel Coronavirus in Patients with DiabetesMellitus, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815040227/chap6-1.gif
According to the preliminary research, coronavirus disease 2019 (COVID 19) has been found to be more severe in patients with diabetes mellitus. Furthermore, COVID-19 might also lead to hyperglycaemia. Along with other risk factors, high blood glucose may also affect immune and inflammatory responses, thus inclining patients to severe COVID-19 witha much higher mortality rate. Angiotensin-converting enzyme 2 (ACE2) receptors are the common entry point for SARS-CoV-2. Recent findings suggest that dipeptidyl peptidase 4 (DPP4) can also act as a binding and entry target. Glucose-lowering agents and anti-viral treatments can alter the risk, but there exist limitations to their use, and its possible interactions with COVID-19 treatments should be carefully assessed. TMPRSS2 and Neuropilin-1, the key components that facilitate SARS-CoV-2 infection, are also the potential targets forthe treatment of COVID-19. Finally, severe acute respiratory syndrome coronavirus 2 infections might represent a worsening factor for people with diabetes, as it can precipitate acute metabolic complications through direct negative effects on cell function. Thus, this chapter deals with the treatment options of diabetes and COVID-19. Most of these conclusions are preliminary, and further investigation of the optimal management in patients with diabetes mellitus is warranted.
-
From This Site
/content/books/9789815040227.chap6dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
